| Bioactivity | Adenylosuccinic acid (Adenylosuccinate; Aspartyl adenylate) is a purine ribonucleoside monophosphate and plays a role in nucleotide cycle metabolite. Adenylosuccinic acid can be converted into fumaric acid through adenylosuccinate lyase. Adenylosuccinic acid has the potential for the study of duchenne muscular dystrophy(DMD)[1]. |
| In Vivo | Adenylosuccinic acid (oral administration; 3-3000 µg/mL; 6 weeks) significantly improves the features of murine DMD, it decreases the number of centronucleated fibres, lipid accumulation, connective tissue infiltration and Ca2+ content of mdx tibialis anterior[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 19046-78-7 |
| Formula | C14H18N5O11P |
| Molar Mass | 463.29 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Timpani CA, et al. Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophy.Sci Rep. 2020 Jan 24;10(1):1125. |
Adenylosuccinic acid
CAS: 19046-78-7 F: C14H18N5O11P W: 463.29
Adenylosuccinic acid (Adenylosuccinate; Aspartyl adenylate) is a purine ribonucleoside monophosphate and plays a role in
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.